01:38 PM EDT, 09/02/2025 (MT Newswires) -- Outlook Therapeutics ( OTLK ) said Tuesday it submitted a Type A meeting request to the US Food and Drug Administration to discuss a complete response letter for a biologics license application resubmission for ONS-5010, an investigational treatment for wet macular degeneration.

The company said it has requested a meeting as it seeks to clarify details regarding confirmatory evidence required by the agency.

Shares of the company were up over 5% in recent Tuesday trading.

Price: 0.90, Change: +0.05, Percent Change: +5.29